ImmunoCellular acquires molecular antibody technology
The technology acquired under the MDC agreement and now owned by the company consists of a platform technology referred to by MDC as DIAAD for the potentially rapid
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
More than 400 patient-specific Gvax-induced antibody responses were identified in the sera of the treated patients by three different biochemical techniques confirming, as previously reported, that Gvax treatment